Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 381 clinical trials
BEACON - ABC in Recurrent Platinum Resistant HGSOC (BEACON)

cell lung cancer, and bladder cancer in Australia. However, this treatment combination is experimental and is not approved to treat ovarian, fallopian tube or peritoneal cancers in any country.

cytoreductive surgery
cancer of the ovary
ovarian epithelial cancer
atezolizumab
ovarian epithelial carcinoma
  • 30 views
  • 14 Feb, 2022
  • 1 location
A Trial of Ipatasertib in Combination With Atezolizumab (IceCAP)

This is a single centre, proof-of-concept phase I trial of atezolizumab in combination with ipatasertib. There are two parts to this study, the dose escalation phase (Part A) and the dose expansion phase (Part B). Part A, will determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D). …

neutrophil count
cancer
PTEN
aptt
platelet count
  • 131 views
  • 22 Apr, 2022
  • 1 location
Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

Checkpoint inhibitor therapy represents a significant advance in cancer care. The interaction between PD-1 and PD-L1 induces immune tolerance, and the inhibition of this interaction is an effective treatment strategy for numerous malignancies. Despite its demonstrated potential, immunotherapy is not currently thought to be an effective intervention in the treatment …

soft tissue sarcoma
mammogram
cancer
trastuzumab
cancer of the ovary
  • 11 views
  • 07 Oct, 2022
  • 1 location
Therapeutic Instillation of Mistletoe (TIM)

The aim of this phase III study is to assess the efficacy of abnobaVISCUM® 900 compared with Mitomycin C (MMC) monotherapy in patients with superficial bladder carcinoma by evaluation of the time to tumor recurrence. Secondary objective is to evaluate the safety of abnobaVISCUM® 900, in particular, to compare the …

  • 58 views
  • 13 May, 2022
  • 23 locations
A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants With Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304) (KEYNOTE-B15)

The purpose of this study is to assess the antitumor efficacy and safety of perioperative enfortumab vedotin (EV) plus pembrolizumab and radical cystectomy (RC) + pelvic lymph node dissection (PLND) compared with the current standard of care (neoadjuvant chemotherapy [gemcitabine plus cisplatin] and RC + PLND) for participants with MIBC …

  • 19 views
  • 24 Oct, 2022
  • 126 locations
  • 16 views
  • 25 Oct, 2022
  • 113 locations
  • 0 views
  • 15 Mar, 2022
  • 1 location
  • 94 views
  • 20 Oct, 2022
  • 1 location
A Phase 3 Study of CG0070 in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus-Calmette-Guerin (BCG) (BOND-003)

To evaluate the activity of intravesical (IVE) administration of CG0070 in patients with tissue pathology confirmed non-muscular invasive bladder cancer (NMIBC) who have Bacillus-Calmette-Guerin

  • 0 views
  • 23 Oct, 2022
  • 58 locations
  • 0 views
  • 22 Oct, 2022
  • 12 locations